CRANBURY, N.J., March 1, 2012 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq:FOLD) today announced it has commenced an underwritten public offering of its common stock. Leerink Swann LLC and Cowen and Company, LLC are acting as joint book-running managers. The Company expects to grant the underwriters a 30-day option to purchase up to an additional 15% of the shares of common stock offered in the public offering to cover over-allotments, if any. The offering is subject to market conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the final size or terms of the offering.
